Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Johnson & Johnson (JNJ)
NYSE:JNJ
Johnson & Johnson (JNJ) Stock Price & Analysis
23,685 Followers
JNJ Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$141.57 - $170.63
Previous Close$146.44
Volume5.49M
Average Volume (3M)7.71M
Market Cap
$352.43B
Enterprise Value$359.85B
Total Cash (Recent Filing)$26.22B
Total Debt (Recent Filing)$33.63B
Price to Earnings (P/E)21.1
Beta0.26
Next Earnings
Jul 17, 2024EPS Estimate
$2.72Last Dividend Ex-Date
May 20, 2024Dividend Yield3.29%
Share Statistics
EPS (TTM)6.94
Shares Outstanding2,406,679,183
10 Day Avg. Volume6,994,432
30 Day Avg. Volume7,707,302
Standard Deviation0.05
R-Squared0.32
Alpha-0.00120
Financial Highlights & Ratios
Price to Book (P/B)-405.89
Price to Sales (P/S)4.20
Price to Cash Flow (P/CF)24.50
P/FCF Ratio30.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue4.01
Enterprise Value/Gross Profit6.14
Enterprise Value/Ebitda28.78
Forecast
1Y Price Target
$175.69Price Target Upside20.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
Johnson & Johnson News
Bulls Say, Bears Say
Bulls Say
Efficacy And SafetyNipocalimab data demonstrates a competitive efficacy profile vs. other FcRn therapies and is supportive of approval in myasthenia gravis.
MedTech AcquisitionThe acquisition is expected to be immediately accretive to total company and JNJ MedTech operating margins, benefiting from SWAV’s high gross margin profile.
OncologyJ&J’s oncology business has a strong long-term outlook due to the continued growth of its multiple myeloma franchise and late-stage/commercial assets entering multi-billion-dollar market opportunities.
Bears Say
Litigation RisksOngoing Talc litigation could be more costly than expected and poses a significant risk to the company's outlook.
Product RecallsJNJ recently recalled its Varipulse PFA catheter in Europe and Japan due to the product not meeting specifications.
Sales PerformanceSome products, like Carvykti and Tecvayli, reported sales significantly below analysts' expectations.
---
Ownership Overview
0.19% Insiders
18.58% Mutual Funds
20.48% Other Institutional Investors
60.75% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
JNJ FAQ
What was Johnson & Johnson’s price range in the past 12 months?
Johnson & Johnson lowest stock price was $141.57 and its highest was $170.63 in the past 12 months.
What is Johnson & Johnson’s market cap?
Currently, no data Available
When is Johnson & Johnson’s upcoming earnings report date?
Johnson & Johnson’s upcoming earnings report date is Jul 17, 2024 which is in 14 days.
How were Johnson & Johnson’s earnings last quarter?
Johnson & Johnson released its earnings results on Apr 16, 2024. The company reported $2.71 earnings per share for the quarter, beating the consensus estimate of $2.656 by $0.054.
Is Johnson & Johnson overvalued?
According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued.
Does Johnson & Johnson pay dividends?
Johnson & Johnson pays a Quarterly dividend of $1.24 which represents an annual dividend yield of 3.29%. See more information on Johnson & Johnson dividends here
What is Johnson & Johnson’s EPS estimate?
Johnson & Johnson’s EPS estimate is $2.72.
How many shares outstanding does Johnson & Johnson have?
Johnson & Johnson has 2,406,679,200 shares outstanding.
What happened to Johnson & Johnson’s price movement after its last earnings report?
Johnson & Johnson reported an EPS of $2.71 in its last earnings report, beating expectations of $2.656. Following the earnings report the stock price went down -2.131%.
Which hedge fund is a major shareholder of Johnson & Johnson?
Among the largest hedge funds holding Johnson & Johnson’s share is Fisher Asset Management LLC. It holds Johnson & Johnson’s shares valued at 1B.
---
Johnson & Johnson Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$175.69 (20.31% Upside)
$175.69 (20.31% Upside)
Blogger Sentiment
Bullish
JNJ Sentiment 87%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.75%
12-Months-Change
Fundamentals
Return on Equity
23.91%
Trailing 12-Months
Asset Growth
-12.25%
Trailing 12-Months
Company Description
Johnson & Johnson
Johnson & Johnson provides healthcare products across three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.
---
JNJ Company Deck
---
JNJ Earnings Call
Q1 2024
0:00 / 0:00
---
JNJ Sales Breakdown
64.30% Innovative Medicine
35.70% MedTech
---
JNJ Stock 12 Month Forecast
Average Price Target
$175.69
▲(20.31% Upside)
Technical Analysis
Best Analysts Covering JNJ
1 Year
1 Year Success Rate
21/23 ratings generated profit
1 Year Average Return
+8.87%
reiterated a buy rating last month
Copying Danielle Antalffy's trades and holding each position for 1 Year would result in 91.30% of your transactions generating a profit, with an average return of +8.87% per trade.
---